8-K filed Feb 23, 2026
Boston Scientific authorizes $1B for stock buybacks
“On February 18, 2026, the Board approved an increase to the Company’s existing authorization to repurchase up to $1.0 billion of the Company’s common stock, par value $0.01 per share (“ Common Stock ”), by an additional $4.0 billion.”
From Boston Scientific’s 8-K filed Feb 23, 2026 · read the filing · all documents
How big is it?
Boston Scientific didn't buy back any stock in the twelve months to Jun 30, 2026, so this program would be a restart.
The amount equals 28% of its free cash flow over the same twelve months ($3.6B).
Its diluted share count is down 1.3% from a year earlier.
An authorization is permission, not a promise: the company can buy less, more slowly, or not at all, and usually doesn't have to say when it buys.
Show as table
| Period | Value |
|---|---|
| Q3 '23 | $0 |
| Q4 '23 | $0 |
| Q1 '24 | $0 |
| Q2 '24 | $0 |
| Q3 '24 | $0 |
| Q4 '24 | $0 |
| Q1 '25 | $0 |
| Q2 '25 | $0 |
| Q3 '25 | $0 |
| Q4 '25 | $0 |
| Q1 '26 | $0 |
| Q2 '26 | $0 |